Long-term Insulin Glargine Therapy in Type 2 Diabetes Mellitus: a Focus on Cardiovascular Outcomes

Overview

Journal Vasc Health Risk Manag

Publisher Dove Medical Press

Specialty Cardiology & Vascular Diseases

Date 2015 Feb 7

PMID 25657589

Citations 7

Authors

Joshua J Joseph

Thomas W Donner

Affiliations

Soon will be listed here.

Abstract

Cardiovascular disease is the leading cause of mortality in type 2 diabetes mellitus. Hyperinsulinemia is associated with increased cardiovascular risk, but the effects of exogenous insulin on cardiovascular disease progression have been less well studied. Insulin has been shown to have both cardioprotective and atherosclerosis-promoting effects in laboratory animal studies. Long-term clinical trials using insulin to attain improved diabetes control in younger type 1 and type 2 diabetes patients have shown improved cardiovascular outcomes. Shorter trials of intensive diabetes control with high insulin use in higher risk patients with type 2 diabetes have shown either no cardiovascular benefit or increased all cause and cardiovascular mortality. Glargine insulin is a basal insulin analog widely used to treat patients with type 1 and type 2 diabetes. This review focuses on the effects of glargine on cardiovascular outcomes. Glargine lowers triglycerides, leads to a modest weight gain, causes less hypoglycemia when compared with intermediate-acting insulin, and has a neutral effect on blood pressure. The Outcome Reduction With Initial Glargine Intervention (ORIGIN trial), a 6.2 year dedicated cardiovascular outcomes trial of glargine demonstrated no increased cardiovascular risk.

Citing Articles

A coarse-to-fine cascade deep learning neural network for segmenting cerebral aneurysms in time-of-flight magnetic resonance angiography.

Chen M, Geng C, Wang D, Zhou Z, Di R, Li F Biomed Eng Online. 2022; 21(1):71.

PMID: 36163014 PMC: 9513890. DOI: 10.1186/s12938-022-01041-3.

Apelin protects against ischemia-reperfusion injury in diabetic myocardium via inhibiting apoptosis and oxidative stress through PI3K and p38-MAPK signaling pathways.

An S, Wang X, Shi H, Zhang X, Meng H, Li W Aging (Albany NY). 2020; 12(24):25120-25137.

PMID: 33342766 PMC: 7803490. DOI: 10.18632/aging.104106.

Update on Management of Type 2 Diabetes for Cardiologists.

Qureshi M, Gammoh E, Shakil J, Robbins R Methodist Debakey Cardiovasc J. 2019; 14(4):273-280.

PMID: 30788013 PMC: 6369620. DOI: 10.14797/mdcj-14-4-273.

Metformin regulates atrial SK2 and SK3 expression through inhibiting the PKC/ERK signaling pathway in type 2 diabetic rats.

Liu C, Hua N, Fu X, Pan Y, Li B, Li X BMC Cardiovasc Disord. 2018; 18(1):236.

PMID: 30545309 PMC: 6293565. DOI: 10.1186/s12872-018-0950-x.

Cardioprotective effect of Notch signaling on the development of myocardial infarction complicated by diabetes mellitus.

Wu F, Yu B, Zhang X, Zhang Y Exp Ther Med. 2017; 14(4):3447-3454.

PMID: 29042932 PMC: 5639400. DOI: 10.3892/etm.2017.4932.

References

Rosenstock J, Fonseca V, McGill J, Riddle M, Halle J, Hramiak I . Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia. 2009; 52(9):1971-3. PMC: 2723677. DOI: 10.1007/s00125-009-1452-2. View

Sato Y, Shiraishi S, Oshida Y, Ishiguro T, Sakamoto N . Experimental atherosclerosis-like lesions induced by hyperinsulinism in Wistar rats. Diabetes. 1989; 38(1):91-6. DOI: 10.2337/diab.38.1.91. View

Ljung R, Talback M, Haglund B, Jonasson J, Gudbjornsdottir S, Steineck G . Insulin glargine use and short-term incidence of breast cancer - a four-year population-based observation. Acta Oncol. 2012; 51(3):400-2. DOI: 10.3109/0284186X.2011.624118. View

Raskin P, Gylvin T, Weng W, Chaykin L . Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev. 2009; 25(6):542-8. DOI: 10.1002/dmrr.989. View

. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995; 44(8):968-83. View

Robinson L, Holt T, Rees K, Randeva H, OHare J . Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open. 2013; 3(1). PMC: 3563145. DOI: 10.1136/bmjopen-2012-001986. View

Horton E, Silberman C, Davis K, Berria R . Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care. 2010; 33(8):1759-65. PMC: 2909058. DOI: 10.2337/dc09-2062. View

Goto A, Arah O, Goto M, Terauchi Y, Noda M . Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013; 347:f4533. DOI: 10.1136/bmj.f4533. View

Shichiri M, Kishikawa H, Ohkubo Y, Wake N . Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000; 23 Suppl 2:B21-9. View

10.

Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V . Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care. 2003; 26(5):1485-9. DOI: 10.2337/diacare.26.5.1485. View

11.

Selvin E, Bolen S, Yeh H, Wiley C, Wilson L, Marinopoulos S . Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008; 168(19):2070-80. PMC: 2765722. DOI: 10.1001/archinte.168.19.2070. View

12.

Taylor K, Heneghan C, Farmer A, Fuller A, Adler A, Aronson J . All-cause and cardiovascular mortality in middle-aged people with type 2 diabetes compared with people without diabetes in a large U.K. primary care database. Diabetes Care. 2013; 36(8):2366-71. PMC: 3714501. DOI: 10.2337/dc12-1513. View

13.

Hollander P, Cooper J, Bregnhoj J, Pedersen C . A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008; 30(11):1976-87. DOI: 10.1016/j.clinthera.2008.11.001. View

14.

Gilbert R, Mann J, Hanefeld M, Spinas G, Bosch J, Yusuf S . Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. Diabetologia. 2014; 57(7):1325-31. DOI: 10.1007/s00125-014-3238-4. View

15.

Yki-Jarvinen H, Dressler A, Ziemen M . Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care. 2000; 23(8):1130-6. DOI: 10.2337/diacare.23.8.1130. View

16.

Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M . Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35(6):1364-79. PMC: 3357214. DOI: 10.2337/dc12-0413. View

17.

Gruden G, Barutta F, Chaturvedi N, Schalkwijk C, Stehouwer C, Witte D . Severe hypoglycemia and cardiovascular disease incidence in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care. 2012; 35(7):1598-604. PMC: 3379603. DOI: 10.2337/dc11-1531. View

18.

. Standards of medical care in diabetes--2014. Diabetes Care. 2013; 37 Suppl 1:S14-80. DOI: 10.2337/dc14-S014. View

19.

Boucai L, Southern W, Zonszein J . Hypoglycemia-associated mortality is not drug-associated but linked to comorbidities. Am J Med. 2011; 124(11):1028-35. PMC: 3200530. DOI: 10.1016/j.amjmed.2011.07.011. View

20.

Bonds D, Miller M, Bergenstal R, Buse J, Byington R, Cutler J . The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010; 340:b4909. PMC: 2803744. DOI: 10.1136/bmj.b4909. View